SAN FRANCISCO--(BUSINESS WIRE)--VIA Pharmaceuticals (NASDAQ: VIAP) a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced funding of a research initiative for a pharmacogenomics sub-study in its VIA-2291 Acute Coronary Syndrome (ACS) trial. This study will be funded by Genome Quebec, a non-profit organization focused on genomics and proteomics research.
